.png?width=1299&height=650&name=ATTD-logo%20(1).png "Digostics - Advanced Technologies and Treatment for Diabetes Logo")
.png?width=200&height=100&name=ATTD-logo%20(1).png "Digostics - Advanced Technologies and Treatment for Diabetes Logo")
Heading to ATTD 2024? Schedule time with Digostics!
We are excited to attend Advanced Technologies and Treatments for Diabetes 2024 where we will proudly present the outcomes of our OGTT home testing collaboration with University Hospital Southampton (UHS).
If you're looking for a better way to deliver diabetes screening, consider booking a meeting with Digostics in Florence!
Improving OGTT Accessibility - An ATTD Poster Presentation on Home Testing
In 2023, a groundbreaking collaboration between Digostics and UHS led to the introduction of the world's first ever gestational diabetes screening programme using home-based oral glucose tolerance testing.
With all women successfully screened during their designated test week and the initiative receiving maximum user preference ratings from both mums-to-be and maternity staff, check out the video project preview ahead of the full results being revealed at ATTD!
Improving OGTT Accessibility - An ATTD Poster Presentation on Home Testing
In 2023, a groundbreaking collaboration between Digostics and UHS led to the introduction of the world's first ever gestational diabetes screening programme using home-based oral glucose tolerance testing.
With all women successfully screened during their designated test week and the initiative receiving maximum user preference ratings from both mums-to-be and maternity staff, check out the video project preview ahead of the full results being revealed at ATTD!
.png?width=200&height=49&name=GTT@home%20Logo%20-%20Digostics%20Orange%20(1).png "GTT@home Logo - Digostics Orange (1)"){kind=small}
The Future of Diabetes Testing, Today
Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.
We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.
GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.
The Future of Diabetes Testing, Today
Digostics uses advanced wireless and sensor technologies to enable safe and secure diabetes testing at home.
We ensure that a greater number of patients can be screened for diabetes without compromising test accuracy or adding to the burden of overworked clinical care teams.
GTT@home is Digostics' breakthrough solution and the world's first and only home OGTT, conveniently providing clinic-equivalent test results.
Revolutionising Diabetes Detection with Home Testing
Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.
Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.
By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.
Revolutionising Diabetes Detection with Home Testing
Digostics' revolutionary new testing platforms offer the world's first and only alternative to in-clinic testing for glucose intolerance by enabling the oral glucose tolerance test (OGTT) to be performed at home.
Our platforms offer the same level of accuracy as clinic tests but without any of the staffing requirements, risks of sample degradation and laboratory delays that often impact clinic testing capacity.
By removing the need for in-clinic tests, we provide a gateway to more extensive testing, faster results and unparalleled opportunities for earlier clinical intervention.
Accurate OGTT Results from the Comfort of Home
Discover how GTT@home provides reliable results that match those obtained in a clinical setting by downloading the associated study.
"GTT@home has an excellent correlation and low bias compared to a reference glucose analyser, with an excellent agreement in categorisation of glucose tolerance."
Professor Steve Luzio, Swansea University
Book a Meeting at ATTD 2024
To learn more about Digostics and GTT@home while at ATTD, book a consultation with Digostics' CEO, James Jackson.